✦ LIBER ✦

Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development

✍ Scribed by Shantaram Kamath; John K. Buolamwini

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 472 KB
Volume: 26
Category: Article
ISSN: 0198-6325
DOI: 10.1002/med.20070

No coin nor oath required. For personal study only.

✦ Synopsis

Conventional anticancer therapy using cytotoxic drugs lacks selectivity and is prone to toxicity and drug resistance. Anticancer therapies targeting aberrant growth factor receptor signaling are gaining interest. The erbB receptor family belongs to the type I, the receptor tyrosine kinases class, and comprises EGFR, HER-2, HER-3, and HER-4. It has been targeted for solid tumor therapy, including breast, ovarian, colon, head-and-neck, and non-small-cell lung cancers. This review summarizes structural aspects of this class of growth factor receptors, their oncogenic expression, and various pharmacological interventions including biological products and small molecules that inhibit these enzymes. We have also discussed various mutations that occur in EGFR and their consequences on anticancer therapy.

📜 SIMILAR VOLUMES

Targeting EGFR and HER-2 Receptor Tyrosi

Targeting EGFR and HER-2 Receptor Tyrosine Kinases for Cancer Drug Discovery and Development

✍ Shantaram Kamath; John K. Buolamwini 📂 Article 📅 2006 🏛 John Wiley and Sons ⚖ 8 KB

Her-2/neu and EGFR tyrosine kinase activ

Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

✍ Gernot Hudelist; Wolfgang J. Köstler; Klaus Czerwenka; Ernst Kubista; Johannes A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 372 KB 👁 2 views

## Abstract Her‐2/__neu__ overexpression in human breast cancer leads to an aggressive biological behavior and poor prognosis. Although the anti‐Her‐2/__neu__ antibody trastuzumab (Herceptin®) has become a valuable therapeutic option for patients with Her‐2/__neu__‐overexpressing breast cancer, man

P2 purinergic receptors on osteoblasts a

P2 purinergic receptors on osteoblasts and osteoclasts: Potential targets for drug development

✍ S. Jeffrey Dixon; Stephen M. Sims 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB

Extracellular nucleotides like ATP bind to cell surface receptors (P2 purinergic receptors) in many tissues. P2X receptor subtypes are intrinsic ion channels that mediate depolarization and influx of Ca 2+ , whereas the P2Y receptor subtypes couple through G proteins to activation of phospholipase C

The dual EGFR/HER-2 tyrosine kinase inhi

The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38

✍ Melissa J. LaBonte; Philipp C. Manegold; Peter M. Wilson; Will Fazzone; Stan G. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 482 KB

## Abstract Members of the human epidermal receptor (HER) family are frequently associated with aggressive disease and poor prognosis in multiple malignancies. Lapatinib is a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and HER‐2. This study evaluated the the

ChemInform Abstract: Discovery and Devel

ChemInform Abstract: Discovery and Development of Folic-Acid-Based Receptor Targeting for Imaging and Therapy of Cancer and Inflammatory Diseases

✍ Philip S. Low; Walter A. Henne; Derek D. Doorneweerd 📂 Article 📅 2008 🏛 John Wiley and Sons ⚖ 15 KB 👁 1 views

Nordihydroguaiaretic acid (NDGA), an inh

Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells

✍ Marianna Zavodovskaya; Michael J. Campbell; Betty A. Maddux; Laura Shiry; Geoffr 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB 👁 2 views

## Abstract We have reported that nordihydroguaiaretic acid (NDGA) inhibits the tyrosine kinase activities of the IGF‐1 receptor (IGF‐1R) and the HER2 receptor in breast cancer cells. Herein, we studied the effects of NDGA on the growth of estrogen receptor (ER) positive MCF‐7 cells engineered to o